Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.

ABSTRACT: In addition to identifying alterations suitable for molecularly targeted therapy (TT), comprehensive genomic profiling (CGP) may convey prognostic/predictive information in advanced non-small-cell lung cancer (aNSCLC). We investigated the impact of tumor suppressor gene alterations (TSGAs) on aNSCLC patients' outcome in a real-world setting. The IMMINENT clinical-genomic database, which provides data on molecular and clinico-pathological features, treatment history, and patients' outcomes of aNSCLC patients who underwent CGP using tissue- or blood-based next-generation sequencing (NGS) between May 2019 and November 2022 was interrogated to assess overall (OS) and progression-free survival (PFS). The Cox proportional hazard model was used to assess the prognostic and predictive role of geno

SUBMITTER: Sposito M 

PROVIDER: S-EPMC12500927 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature